Predictors of psoriatic arthritis development in psoriasis patients: The role of biological therapy in the pathological process

This article is dedicated to the risk factors for psoriatic arthritis development in psoriasis patients, as well as current biotherapeutic options for moderate to severe course of psoriasis and psoriatic arthritis in the absence of response to traditional therapy. The etiology and pathogenetic mechanisms of psoriasis and psoriatic arthritis are considered in the analytical part of the article. The disease is widespread and affects up to 11% of the world's population. One of the most common and severe comorbid conditions is psoriatic arthritis (PsA), which develops in one third of patients with psoriasis. PsA is a chronic potentially severe inflammatory disease of the musculoskeletal system characterized by such clinical manifestations as damage to the axial (spondylitis, sacroiliitis) and peripheral joints (arthritis, dactyl), enthesitis, accompanied by psoriatic skin rashes and onychodystrophy. The disease can develop both before and after the manifestation of skin manifestations. PsA is a disease with a progressive course that can lead to disability and the development of irreversible changes, therefore it requires timely diagnosis, taking into account risk factors and preclinical manifestations, the appointment of effective treatment, and an interdisciplinary approach to therapy. Modern drugs used in the treatment of PsA are aimed at reducing inflammation, maintaining control over the disease and should inhibit destructive processes in the joints, improving the quality of life of patients, meeting modern requirements for efficacy and safety, and not pose a heavy financial burden. The article presents two clinical observations of prescribing disease-modifying treatment to patients with psoriasis and a high risk of PsA and its subclinical manifestations. This article presents two clinical case reports on the treatments of long-lasting psoriasis vulgaris in men with a history of failure to respond to glucocorticosteroids (GCS) and cytostatics. They were prescribed systemic biologic drug therapy, which showed the expected results.

1. Mankia K, Siddle HJ, Kerschbaumer A, Alpizar Rodriguez D, Catrina AI, Cañete JD et al. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Ann Rheum Dis. 2021;80(10):1286–1298. https://doi.org/10.1136/annrheumdis-2021-220884.

2. Кубанов АА, Насонов ЕЛ, Бакулев АЛ, Знаменская ЛФ, Карамова АЭ, Коротаева ТВ и др. Псориатический артрит: клинические рекомендации. 2023.

3. Khismatullina ZR, Koreshkova KM. Predictors of psoriatic arthritis. Klinicheskaya Dermatologiya i Venerologiya. 2021;20(5):7–15. (In Russ.) https://doi.org/10.17116/klinderma2021200517.

4. Askin O, Engin B, Ozdede A, Kartal SP, Ugurlu S, Akbulut TO et al. Relationship of psoriatic arthritis with nail and scalp involvement in Turkish psoriasis patients: Multicentered cross-sectional study. Medicine. 2024;103(29):e38832. https://doi.org/10.1097/MD.0000000000038832.

5. FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59. https://doi.org/10.1038/s41572-021-00293-y.

6. Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162–1170. https://doi.org/10.1136/ard-2023-224148.

7. Perez-Chada LM, Haberman RH, Chandran V, Rosen CF, Ritchlin C, Eder L et al. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nat Rev Rheumatol. 2021;17(4):238–243. https://doi.org/10.1038/s41584-021-00578-2.

8. McGonagle DG, Zabotti A, Watad A, Bridgewood C, De Marco G, Kerschbaumer A, Aletaha D. Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free? Ann Rheum Dis. 2022;81(1):7–10. https://doi.org/10.1136/annrheumdis-2021-221255.

9. Ogdie A, Rozycki M, Arndt T, Shi C, Kim N, Hur P. Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis. Arthritis Res Ther. 2021;23(1):252. https://doi.org/10.1186/s13075-021-02628-2.

10. Merola JF, Patil D, Egana A, Steffens A, Webb NS, Gottlieb AB. Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database. Dermatol Ther. 2023;13(11):2635–2648. https://doi.org/10.1007/s13555-023-01025-8.

11. Cozzi G, Scagnellato L, Lorenzin M, Collesei A, Oliviero F, Damasco A et al. Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound. Front Med. 2024;11:1482894. https://doi.org/10.3389/fmed.2024.1482894.

12. Lorenzin M, Ometto F, Ortolan A, Felicetti M, Favero M, Doria A et al. An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Ther Adv Musculoskelet Dis. 2020;12:1759720X20934277. https://doi.org/10.1177/1759720X20934277.

13. Ogdie A, Harrison RW, McLean RR, Lin TC, Lebwohl M, Strober BE et al. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. J Am Acad Dermatol. 2022;87(6):1303–1311. https://doi.org/10.1016/j.jaad.2022.07.060.

14. Temel B, Adisen E, Gonen S. HLA-Cw6 Status and Treatment Responses Between Psoriasis Patients. Indian J Dermatol. 2021;66(6):632–637. https://doi.org/10.4103/ijd.IJD_282_21.

15. Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706–719. https://doi.org/10.1136/ard-2024-225531.

16. Alharbi S, Ye JY, Lee KA, Chandran V, Cook RJ, Gladman DD. Remission in psoriatic arthritis: Definition and predictors. Semin Arthritis Rheum. 2020;50(6):1494–1499. https://doi.org/10.1016/j.semarthrit.2020.01.012.

17. Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760–774. https://doi.org/10.1136/ard-2024-225534.

18. Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Similarities and differences. Joint Bone Spine. 2023;90(1):105469. https://doi.org/10.1016/j.jbspin.2022.105469.

19. Wendling D, Hecquet S, Fogel O, Letarouilly JG, Verhoeven F, Pham T et al. 2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. Joint Bone Spine. 2022;89(3):105344. https://doi.org/10.1016/j.jbspin.2022.105344.